Two drug injectable regimen for HIV maintenance therapy meets endpoint

Global HIV company ViiV Healthcare today announced that the Phase IIb study LATTE 2 (NCT02120352), undertaken with the Janssen unit of US health care giant Johnson & Johnson (NYSE: JNJ), met its primary endpoint at 32 weeks.

ViiV is a joint venture company majority-owned by UK pharma major GlaxoSmithKline (LSE: GSK), with partners Pfizer and Shionogi.

These results show that the investigational, long acting, injectable formulations of cabotegravir (ViiV) and rilpivirine (Janssen) were comparable in maintaining viral suppression rates to a three drug oral regimen of investigational cabotegravir and two nucleoside reverse transcriptase inhibitors (NRTIs). The 32 week results of LATTE 2 will be presented at a forthcoming scientific conference. ViiV Healthcare and Janssen Sciences Ireland are collaborating to conduct LATTE 2.